Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Cash & Current Investments (2020 - 2023)

Cullinan Therapeutics (CGEM) has 4 years of Cash & Current Investments data on record, last reported at $466.4 million in Q3 2023.

  • For Q3 2023, Cash & Current Investments fell 48.7% year-over-year to $466.4 million; the TTM value through Sep 2023 reached $466.4 million, down 48.7%, while the annual FY2022 figure was $467.3 million, 60.88% up from the prior year.
  • Cash & Current Investments reached $466.4 million in Q3 2023 per CGEM's latest filing, down from $841.8 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $909.3 million in Q3 2022 and bottomed at $210.2 million in Q4 2020.
  • Average Cash & Current Investments over 4 years is $560.2 million, with a median of $510.5 million recorded in 2022.
  • Peak YoY movement for Cash & Current Investments: skyrocketed 157.92% in 2022, then plummeted 48.7% in 2023.
  • A 4-year view of Cash & Current Investments shows it stood at $210.2 million in 2020, then soared by 38.18% to $290.5 million in 2021, then surged by 60.88% to $467.3 million in 2022, then dropped by 0.18% to $466.4 million in 2023.
  • Per Business Quant database, its latest 3 readings for Cash & Current Investments were $466.4 million in Q3 2023, $841.8 million in Q2 2023, and $659.3 million in Q1 2023.